Association between biomarkers of iron status and cardiometabolic risk in Spanish children aged 9–10 years. The ELOIN study

被引:0
作者
Honorato Ortiz-Marrón
Gloria Cabañas Pujadas
Encarnación Donoso Navarro
Mar Burreros García
María Isabel Herreros Álvaro
Alma María Mejía Fernández de Velasco
Ana Cornejo Gutiérrez
Iñaki Galán
机构
[1] Directorate-General of Public Health. Ministry of Health of Community of Madrid,Cardiovascular Disease Surveillance Technical Unit
[2] Puerta de Hierro University Hospital,Clinical Analysis and Biochemistry Service
[3] Ministry of Health of Community of Madrid,Health Center Collado Mediano. Collado Mediano
[4] Ministry of Health of Community of Madrid,Health Center Daroca
[5] Ministry of Health of Community of Madrid,Health Center Aranjuez. Aranjuez
[6] Health Center Barcelona. Móstoles. Ministry of Health of Community of Madrid,National Centre for Epidemiology
[7] Institute of Health Carlos III. Madrid,Department of Preventive Medicine and Public Health. Faculty of Medicine
[8] Universidad Autónoma de Madrid (IdiPaz),undefined
[9] Autonomous University of Madrid),undefined
来源
European Journal of Pediatrics | 2023年 / 182卷
关键词
Iron markers; Ferritin; Transferrin; Transferrin saturation; Cardiac risk; Children;
D O I
暂无
中图分类号
学科分类号
摘要
The relationship between iron metabolism and cardiometabolic risk factors has been scarcely studied in children, and the results are controversial. The objective of this study was to evaluate the association between iron parameters and lipid, glycemic and blood pressure alterations in the pediatric population. This was a cross-sectional study of 1954 children between 9 and 10 years of age in Madrid (Spain), participants in a longitudinal study of childhood obesity. Iron metabolism parameters, i.e., serum iron (Is), ferritin (Fs), transferrin (Tf) and transferrin saturation (STf) and lipid, glycemic and blood pressure profiles were evaluated. Odds ratios (ORs) were estimated using logistic regression models adjusted for sociodemographic characteristics, diet, physical activity, C-reactive protein and body mass index. Compared with the participants in the low Is and STf tertiles, those in the upper tertiles had a lower risk of low HDL-Chol (OR: 0.34; 95%CI: 0.17; 0.67) and OR: 0.44 (95%CI: 0.23; 0.84), respectively, and children in the upper Fs tertile had an OR of 2.07 (95%CI: 1.16; 3.68) for low HDL-Chol. Children in the highest Is and STf tertiles had a lower risk of prediabetes [OR: 0.63 (95%CI: 0.41; 0.97) and OR: 0.53 (95%CI: 0.34; 0.82)] and insulin resistance (IR) (OR: 0.37; 95%CI: 0.22; 0.64), and those in the upper Tf tertile had a higher risk of IR (OR: 1.90; 95%CI: 1.16; 3.12). An increased risk of hypertension was found only in children in the upper Fs tertile (OR: 1.46; 95%CI: 1.01; 2.13).
引用
收藏
页码:5649 / 5659
页数:10
相关论文
共 116 条
[1]  
Milto IV(2016)Molecular and Cellular Bases of Iron Metabolism in Humans Biochem Biokhimiia 81 549-564
[2]  
Suhodolo IV(2023)Iron status in chronic inflammatory disease: therapeutic implications Pol Arch Intern Med 133 16430-272
[3]  
Prokopieva VD(2021)On Iron Metabolism and Its Regulation Int J Mol Sci 22 4591-165
[4]  
Klimenteva TK(2020)Iron metabolism and iron disorders revisited in the hepcidin era Haematologica 105 260-318
[5]  
Cappellini MD(2021)Iron and cardiovascular diseases J Cardiol 77 160-394
[6]  
Scaramellini N(2013)Ferritin levels and risk of type 2 diabetes mellitus: an updated systematic review and meta-analysis of prospective evidence Diabetes Metab Res Rev 29 308-631
[7]  
Motta I(2014)Association of iron indices and type 2 diabetes: a meta-analysis of observational studies Diabetes Metab Res Rev 30 372-106
[8]  
Vogt ACS(2021)Iron in Cardiovascular Disease: Challenges and Potentials Front Cardiovasc Med 8 623-210
[9]  
Arsiwala T(2021)Serum Ferritin and the Risk of Metabolic Syndrome: A Systematic Review and Dose-Response Meta-Analysis of Cross-sectional Studies Biomed Environ Sci BES 34 97-2374
[10]  
Mohsen M(2018)Ferritin, metabolic syndrome and its components: A systematic review and meta-analysis Atherosclerosis 275 483-523